Schering-Plough, Incyte Report Positive Mid-Stage Data For CCR5 Antagonists
This article was originally published in The Pink Sheet Daily
Executive Summary
Both Schering’s vicriviroc and Incyte’s INCB9471 CCR5 antagonist candidates to treat HIV beat placebo in Phase II trials.
You may also be interested in...
Schering Moves Vicriviroc Phase III Program Forward In HIV
Company has initiated two Phase III studies of the CCR5 receptor antagonist in treatment-experienced HIV patients.
Schering Moves Vicriviroc Phase III Program Forward In HIV
Company has initiated two Phase III studies of the CCR5 receptor antagonist in treatment-experienced HIV patients.
Pfizer’s Selzentry Wins FDA Approval For HIV
First-in-class CCR5 antagonist will be available by mid-September with a wholesale acquisition cost of $29/day based on twice-a-day dosing, Pfizer tells “The Pink Sheet” DAILY.